Literature DB >> 20690098

Successful use of intra-aortic counter pulsation therapy for intractable ventricular arrhythmia in patient with severe left ventricular dysfunction and normal coronary arteries.

Deepak Goyal1, Sunil K Nadar, Ben Wrigley, Sudheer Koganti, Prithwish Banerjee.   

Abstract

Intra-aortic balloon pumps (IABP) are commonly used in the setting of an acute myocardial infarction that is complicated by cardiogenic shock or mechanical complications such as a ventricular septal defect or papillary muscle rupture. IABP has also been shown to be useful in patients with refractory and hemodynamically unstable ventricular arrhythmias and refractory post-myocardial infarction angina. We report a case in which IABP was used in a patient with dilated cardiomyopathy and normal coronary arteries, who presented with persistent, recurrent and refractory ventricular tachycardia. His ventricular tachycardia settled immediately with the use of IABP therapy. He subsequently had an implantable defibrillator. The use of IABP is associated with favorable changes in the left ventricular wall tension and reduction in afterload, which could reduce the excitability of the myocardium, thus making it less prone to arrhythmias. The use of IABP is relatively safe and should be considered in patients with refractory ventricular arrhythmias, even if it is not associated with ischemia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20690098

Source DB:  PubMed          Journal:  Cardiol J        ISSN: 1898-018X            Impact factor:   2.737


  2 in total

Review 1.  IABP: history-evolution-pathophysiology-indications: what we need to know.

Authors:  H Parissis; V Graham; S Lampridis; M Lau; G Hooks; P C Mhandu
Journal:  J Cardiothorac Surg       Date:  2016-08-04       Impact factor: 1.637

2.  Can we have a rationalized selection of intra-aortic balloon pump, Impella, and extracorporeal membrane oxygenation in the catheterization laboratory?

Authors:  Giulio Russo; Francesco Burzotta; Cristina Aurigemma; Daniela Pedicino; Enrico Romagnoli; Carlo Trani
Journal:  Cardiol J       Date:  2020-12-21       Impact factor: 2.737

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.